精密心脏病学:针对HFmrEF和HFpEF的表型向治疗方法
Giuseppe M C Rosano1,2, Cristiana Vitale3, Ilaria Spoletini4
1Department of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome, Rome, Italy.
International journal of heart failure
|May 2, 2024
概括
心力衰竭与中等范围和保存的喷射分数 (HFmrEF/HFpEF) 缺乏向治疗. 精准医学专注于患者子组和特定机制,为开发有效治疗这些常见心脏病的途径提供了有希望的途径.
科学领域:
- 心脏病学 心脏病学
- 精准医学是一门精准的医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 中等射出率 (HFmrEF) 和保存射出率 (HFpEF) 的心力衰竭占所有心力衰竭病例的一半以上.
- 目前对HFmrEF和HFpEF的治疗选择有限,主要包括-葡萄糖共运输体2抑制剂和利尿剂.
- HFmrEF和HFpEF的异质性需要个性化治疗策略.
研究的目的:
- 审查用于治疗HFmrEF和HFpEF的精密医学方法.
- 探索针对不同的HFmrEF和HFpEF患者子组的特定治疗策略.
- 突出精确表型化在推进心力衰竭治疗中的重要性.
主要方法:
- 对HFmrEF和HFpEF机制和治疗方法的当前文献的综述.
- 讨论患者分层的精确表型化策略.
- 探索有针对性的干预措施,包括抗炎,抗纤维素,If抑制和矿物质皮质体受体对抗作用.
主要成果:
- HFmrEF和HFpEF是复杂的疾病,需要定制的治疗干预措施.
- 特定的机制和患者个人资料 (例如,肥胖,心房动,慢性病) 可以指导治疗选择.
- 精确的表型定型使得开发更有效,更有针对性的疗法成为可能.
结论:
- 精准医学为管理HFmrEF和HFpEF提供了一个范式转变.
- 基于精确的患者表型定制的量身定制疗法对于改善结果至关重要.
- 未来的临床试验应纳入精确的表型,以推进心力衰竭治疗,超出一般化方法.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
159
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
159
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:30Pulmonary Hypertension: Classification and Pathogenesis
173
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
173
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156